BPC-157 is a synthetic 15-amino-acid peptide (a pentadecapeptide) whose sequence corresponds to a fragment of a protein found in human gastric juice. In preclinical research it is studied — primarily in rodent models — for tendon, vascular, and gastrointestinal repair via three proposed pathways: nitric oxide (NO) signalling, VEGF/VEGFR2-driven angiogenesis, and growth-hormone-receptor modulation. Body Pharm supplies BPC-157 strictly for in-vitro and preclinical research use — it is not a medicine and is not intended for human or veterinary use.
This guide covers what BPC-157 is and where the sequence comes from, how it is proposed to work based on animal research, what the human evidence does and does not show, and how the peptide fits within the Body Pharm range.
What is BPC-157?
BPC-157 is a fully chemically synthesised oligopeptide — not extracted from gastric tissue. A notable property is its reported stability in gastric acid, unusual among peptides, which has driven interest in oral as well as injectable research formulations because most peptides degrade rapidly in the stomach. The compound appears in the literature under several synonyms, including Body Protection Compound 157, bepecin, and the development code PL 14736.
The peptide was first characterised by Predrag Sikirić and colleagues at the University of Zagreb, whose group has produced the majority of the published BPC-157 literature since the 1990s. Early work focused on gastric cytoprotection in rat models, later expanding to tendon, vascular, and central-nervous-system injury paradigms. A key caveat is that most mechanistic claims still trace back to this single research programme, with limited independent replication.
What it is not
BPC-157 is not a growth hormone, not a steroid, and not a small-molecule drug — it is a chain of amino acids. It is also not a naturally occurring peptide in the body; the 15-amino-acid sequence exists only as a synthetic construct designed around a fragment of the parent BPC protein.
Proposed mechanisms of action
BPC-157 is studied through three distinct biochemical pathways, each mapping preferentially to a different tissue type. The evidence base for each is overwhelmingly preclinical — rodent models supply nearly all mechanistic data.
Nitric oxide pathway — gut mucosa and vascular integrity
The NO mechanism is the most extensively replicated. Multiple studies report that BPC-157 interacts with the NO system and modulates Akt/eNOS signalling in rat gastric and vascular injury models, maintaining vascular integrity and counteracting injury-induced vascular leakage. The tissue most plausibly involved is gut mucosa, where NO-driven vasodilation underpins cytoprotection, and secondarily endothelium during ischaemia-reperfusion injury. No human studies have directly measured eNOS or NO bioavailability changes following administration, so the pathway remains theoretical in people.
VEGF upregulation — tendon, ligament, and poorly vascularised tissue
Preclinical work shows that BPC-157 enhances VEGFR2 activity and promotes angiogenesis via Akt-eNOS signalling in rodent tendon, muscle, and vascular injury models, with increased vessel density reported after tendon or muscle damage. This pathway maps most plausibly to tendon and ligament repair, where baseline vascularity is poor and new capillary formation limits healing. There are no VEGF-pathway studies in human cell lines or human subjects.
Growth-hormone-receptor modulation — muscle and bone
This pathway rests almost entirely on a single study in rat tendon fibroblasts, which reported dose- and time-dependent increases in growth-hormone-receptor (GHR) expression at both mRNA and protein levels following exposure. The finding was not extended in vivo or to human cells, so it remains the least validated of the three, most plausibly relevant to muscle and bone where IGF-1-mediated anabolic signalling depends on receptor density.
| Mechanism | Primary pathway | Tissue most studied | Evidence level |
|---|---|---|---|
| NO upregulation | Akt/eNOS → NO bioavailability | Gut mucosa, endothelium | Animal-only (multi-study) |
| VEGF upregulation | VEGFR2 → angiogenesis | Tendon, ligament | Animal-only (multi-study) |
| GH-receptor modulation | Increased GHR expression | Muscle, bone, tendon fibroblasts | Animal cells, single study |
What the animal studies show
Every meaningful BPC-157 observation on record comes from animal models. Tendon and ligament work is the strongest claim by volume of replication, via VEGFR2 and Akt-eNOS signalling in rat injury models. Gut mucosal protection is where the peptide originated — rat models of gastric ulceration and injury show maintenance of vascular integrity across a wide dose range. Broad anti-inflammatory effects are treated as a downstream consequence of vascular and cytoprotective actions rather than a distinct mechanism. Bone-healing and neuroprotective claims are the thinnest, resting on limited rodent data. Across all of this, the gap between rodent models and any human outcome is substantial and uncharacterised.
Handling and research framing
In a laboratory setting BPC-157 is typically supplied as a lyophilised powder and reconstituted with bacteriostatic or sterile water before use. Standard peptide-handling practice applies: add diluent gently down the vial wall rather than onto the cake, avoid shaking, keep reconstituted material refrigerated and protected from light, and avoid repeated freeze-thaw cycles. Because product quality varies widely across the research-peptide market, using a consistently produced, quality-controlled vial helps keep experimental conditions reproducible.
BPC-157 vs. TB-500
BPC-157 and TB-500 are distinct preclinical peptides with different origins and mechanisms, often researched together. BPC-157 centres on NO/Akt-eNOS signalling, VEGFR2-mediated angiogenesis, and GHR modulation. TB-500 is a synthetic fragment of thymosin beta-4 that acts primarily through actin sequestration and regulation of cell migration — a fundamentally different pathway affecting cytoskeletal dynamics rather than growth-factor signalling. Combination evidence is weaker than the already limited evidence for either compound alone, since the two have never been studied together in humans.
BPC-157 in the Body Pharm range
Body Pharm pairs BPC-157 with TB-500 in a single research pen. See the BPC-157 + TB-500 32 Pen — a combined format used to study the two repair-research peptides together.
Research use only
BPC-157 is not registered as a medicine by any regulatory authority and has no approved human therapeutic indication. All peptides are supplied strictly for laboratory research use only — not for human or veterinary use, and not for consumption, diagnosis, or treatment.